Ocugen: Downgrading After OCU410 Data Release [Seeking Alpha]
Ocugen, Inc. (OCGN)
Company Research
Source: Seeking Alpha
Preliminary phase 2 ArMaDa data showed a 46% reduction in lesion growth, but lacked dose-dependent efficacy and had a small sample size. Key catalysts include final ArMaDa data [March 2026], OCU410ST interim [Q3 2026] and topline [Q2 2027], and OCU400 RP topline [Q1 2027]. Company's cash runway extends to Q4 2026 [potentially Q2 2027 with warrant exercise], but quarterly burn and multiple late-stage trial risks remain. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Rasi Bhadramani/iStock via Getty Images The last time I spoke about Ocugen OCGN ) it was with respect to a S eeking Alpha article entitled " Ocugen: Maintaining 'Buy' Rating On Positive OCU410 ST Regulatory Developments ". The reason why was because the company received alignment More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you l
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story [Yahoo! Finance]Yahoo! Finance
- Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts [Seeking Alpha]Seeking Alpha
- Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 3/5/26 - Form 3
- 3/4/26 - Form S-8
- 3/4/26 - Form 10-K
- OCGN's page on the SEC website